Literature DB >> 24101156

Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice.

Ana C Issy1, João Francisco C Pedrazzi, Bruno H Yoneyama, Elaine A Del-Bel.   

Abstract

RATIONALE: Nitric oxide (NO) modulates the dopamine uptake and release processes and appears to be implicated in dopamine-related pathologies, such as schizophrenia. However, it is unclear whether there is excess or deficient NO synthesis in schizophrenia pathophysiology. Analyses of the intracellular pathways downstream of NO system activation have identified the cyclic nucleotide cyclic guanosine monophosphate (cGMP) as a possible target for drug development. Defects in the sensorimotor gating of the neural mechanism underlying the integration and processing of sensory information have been detected across species through prepulse inhibition (PPI).
OBJECTIVES: The aim of this study was to investigate the effects of NO/cGMP increase on sensorimotor gating modulation during dopamine hyperfunction.
METHODS: Mice were treated with NO donors and subjected to the PPI test. Treatment with the NO donor sodium nitroprusside was preceded by pretreatment with a soluble guanylate cyclase (sGC) inhibitor. Additionally, the mice were treated with NO donors and phosphodiesterases inhibitors prior to amphetamine treatment.
RESULTS: Pretreatment with the NO donors enhanced the PPI response and attenuated the amphetamine-disruptive effects on the PPI. The sGC inhibitor did not modify the sodium nitroprusside effects. Additionally, the cGMP increase induced by a specific phosphodiesterase inhibitor did not modify the amphetamine-disruptive effect.
CONCLUSIONS: This study provides the first demonstration that an increase in NO can improve the PPI response and block the amphetamine-disruptive effects on the PPI response. Our data are consistent with recent clinical results. However, these effects do not appear to be related to an increase in cGMP levels, and further investigation is thus required.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24101156     DOI: 10.1007/s00213-013-3277-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  85 in total

1.  Presidential Address, 1974. The more or less startling effects of weak prestimulation.

Authors:  F K Graham
Journal:  Psychophysiology       Date:  1975-05       Impact factor: 4.016

2.  Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study.

Authors:  Jesus Ramirez; Rodrigo Garnica; Marie-Catherine Boll; Sergio Montes; Camilo Rios
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

3.  Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.

Authors:  Christine A Strick; Larry C James; Carol B Fox; Thomas F Seeger; Frank S Menniti; Christopher J Schmidt
Journal:  Neuropharmacology       Date:  2009-09-16       Impact factor: 5.250

Review 4.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

5.  The neuronal selective nitric oxide synthase inhibitor, Nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice.

Authors:  Daniel Klamer; Jörgen A Engel; Lennart Svensson
Journal:  Eur J Pharmacol       Date:  2004-10-25       Impact factor: 4.432

Review 6.  Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy.

Authors:  Hans-Gert Bernstein; Gerburg Keilhoff; Johann Steiner; Henrik Dobrowolny; Bernhard Bogerts
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-11       Impact factor: 4.388

Review 7.  cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour.

Authors:  Thomas Kleppisch; Robert Feil
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.

Authors:  M P Kelly; J M Stein; C G Vecsey; C Favilla; X Yang; S F Bizily; M F Esposito; G Wand; S J Kanes; T Abel
Journal:  Mol Psychiatry       Date:  2008-11-25       Impact factor: 15.992

9.  Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.

Authors:  M Weber; M Breier; D Ko; N Thangaraj; D E Marzan; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2008-12-09       Impact factor: 4.530

10.  Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha.

Authors:  Thomas J Gould; Scott P Bizily; Jan Tokarczyk; Michele P Kelly; Steven J Siegel; Stephen J Kanes; Ted Abel
Journal:  Neuropsychopharmacology       Date:  2004-03       Impact factor: 7.853

View more
  6 in total

1.  Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain.

Authors:  Mariana C Diana; Fernanda F Peres; Veronica Justi; Rodrigo A Bressan; Acioly L T Lacerda; José Alexandre Crippa; Jaime E C Hallak; Vanesssa Costhek Abilio
Journal:  CNS Neurosci Ther       Date:  2018-04-14       Impact factor: 5.243

2.  The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats.

Authors:  Aikaterini Trevlopoulou; Ntilara Touzlatzi; Nikolaos Pitsikas
Journal:  Psychopharmacology (Berl)       Date:  2015-12-19       Impact factor: 4.530

3.  Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia.

Authors:  Ludmyla Kandratavicius; Priscila Alves Balista; Daniele Cristina Wolf; Joao Abrao; Paulo Roberto Evora; Alfredo Jose Rodrigues; Cristiano Chaves; Joao Paulo Maia-de-Oliveira; Joao Pereira Leite; Serdar Murat Dursun; Glen Bryan Baker; Francisco Silveira Guimaraes; Jaime Eduardo Cecilio Hallak
Journal:  BMC Neurosci       Date:  2015-03-07       Impact factor: 3.288

4.  Dopamine Receptor Blockade Attenuates Purinergic P2X4 Receptor-Mediated Prepulse Inhibition Deficits and Underlying Molecular Mechanisms.

Authors:  Sheraz Khoja; Liana Asatryan; Michael W Jakowec; Daryl L Davies
Journal:  Front Cell Neurosci       Date:  2019-07-23       Impact factor: 5.505

5.  Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia.

Authors:  Zhi-Min Yu; Ying Zhao; Jin-Qiong Zhan; Tao Luo; Jian-Wen Xiong; Bin Yu; Bo Wei; Yuan-Jian Yang
Journal:  Front Psychiatry       Date:  2019-01-10       Impact factor: 4.157

Review 6.  The Nitric Oxide (NO) Donor Sodium Nitroprusside (SNP) and Its Potential for the Schizophrenia Therapy: Lights and Shadows.

Authors:  Elli Zoupa; Nikolaos Pitsikas
Journal:  Molecules       Date:  2021-05-26       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.